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Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly being identified
worldwide and pose a major threat to the treatment of infectious diseases and to infection control within heath care facilities.1 In 2014, a meta-analysis showed mortality rates
attributable to CRE to be 26%–44%.2 Frequency of CRE is increasing in worldwide.3,4
In Pakistan, the rates have been increasing steadily, data from our hospital showed
increase in carbapenem-resistant Escherichia coli, Enterobacter spp. and Klebsiella
pneumoniae from 5%, 7% and 15% in 2013 to 6%, 23% and 22% by 2015, respectively.5
With increasing antimicrobial resistance and given the paucity of new drugs,
the focus of management has shifted to older agents.6 Currently, such antibiotics in
use in Pakistan include colistin and fosfomycin. It has earlier been shown that treatment of CRE with combination of carbapenem and colistin is associated with better
outcomes7 leading to increased use of colistin in clinical practice.8 Fosfomycin has
traditionally been used to treat urinary tract and gastrointestinal infections. A meta231
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Introduction: Management of infections with carbapenem-resistant Enterobacteriaceae (CRE)
is challenging. In recent times, agents such as colistin and fosfomycin have been used in combination with other antibiotics to treat such infections. In this study, we aim to seek frequency
of colistin and fosfomycin resistance in CRE from Pakistan.
Methods: This study was conducted at clinical laboratories, Aga Khan University Hospital. In
total, 251 CRE were included in the study. Colistin minimum inhibitory concentrations (MICs)
were performed using broth microdilution (BMD) method and VITEK® 2 system, whereas
fosfomycin susceptibility was performed using Kirby–Bauer method. MIC50 and MIC90 were
calculated for colistin and agreement between VITEK and BMD was also calculated.
Results: Out of 251 strains colistin MIC of ≥4 µg/mL was seen in 40 (15.9%). Of these strains
20 (50%) were Klebsiella pneumoniae. Colistin MIC50 and MIC90 were found to be 0.5 and
16 µg/mL, respectively. BMD and VITEK 2 showed 100% categorical agreement. Essential
agreement was 88.5% with kappa score 0.733 indicating strong agreement between VITEK
and BMD. 31 out of 251 (12.3%) CREs were resistant to fosfomycin.
Conclusion: Study shows frequency of colistin and fosfomycin resistance to be 15.9% and
12.3%, respectively. In countries where rate of CREs is high, emerging resistance against these
last resort antibiotics is alarming as it leaves clinicians with almost no options to manage such
multidrug resistant and extensively drug resistant infections.
Keywords: emerging drug resistance, colistin resistance, fosfomycin resistance, carbapenam
resistant enterobacteriaceae, salvage antibiotics
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analysis including 62 studies, showed utility of fosfomycin
either alone or in combination with other antibiotics for
the treatment of pneumonia, osteomyelitis, meningitis, ear,
nose, throat infections and gynecological infections,9 hence,
identifying fosfomycin as having potential for treatment
of invasive infections. In February 2010, intravenous (IV)
fosfomycin was prospectively evaluated for the treatment of
carbapenem-resistant K. pneumoniae wherein all patients
had bacteriological clearance with no adverse reactions.10
Given rising antimicrobial resistance and reports of CRE,
this study was designed to evaluate the frequency of colistin
and fosfomycin resistance in carbapenem-resistant Gramnegative bacterial infections in our population.

Materials and methods
Study setting
This was a prospective study conducted on archived bacterial isolates from clinical specimens received in the Clinical
Microbiology Laboratory, Aga Khan University. The archived
strains were stored at −80°C in glycerol phosphate broth and
were revived on MacConkey agar before use.

Bacterial isolates
All CRE isolated from January 2015 to August 2016 were
included. CREs were defined using CLSI 2015 cut-offs
for ertapenem, imipenem or meropenem.11 Identification
of strains included in the study was done using API 20E
system. Strains with inherent resistance to colistin such as
those belonging to genus Proteus, Providencia and Serratia
were excluded from the study.
• Susceptibility testing: Carbapenem susceptibilities were
performed by disc diffusion (Kirby–Bauer) method on
Mueller Hinton agar11 and by VITEK 2 system.12 Isolates
were labeled as CREs by disc diffusion zone diameters
and by VITEK minimum inhibitory concentrations
(MICs). For interpretation CLSI 2015 breakpoints for
imipenem, ertapenem and meropenem, that is, for ertapenem disc diameter ≤19 mm or MIC ≥1, for imipenem
and meropenem disc diameter ≤21 mm or MIC ≥2 were
used.11
• Colistin susceptibility was performed as follows: broth
microdilution using 96-well microtiter plates to perform
MICs using cation adjusted Mueller Hinton broth as
culture medium. Drug concentration ranging from 0.03
to 16 µg/mL was used. MICs were performed in batches
of 10−20 strains per batch, 5 days a week from July 2016
till August 2016 on archived strains. Colistin sulfate
powder was obtained from Sigma-Aldrich Co. (St Louis,
232
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MO, USA). ATCC E. coli 25922 and ATCC P. aeruginosa
27853 were used as quality control strains. Results were
read at 24 hours and interpreted using colistin cut-offs
for Enterobacteriaceae in EUCAST 2016, that is, MIC ≤2
as sensitive.13 Colistin MICs were also determined using
automated VITEK 2 system. Results were compared with
broth microdilution. Broth microdilution was used as the
gold standard. Agreement between broth and VITEK was
calculated.
• Fosfomycin susceptibility was tested by disc diffusion
method using fosfomycin trometamol disc (200 µg)
(Thermo Fisher Scientific, Waltham, MA, USA) containing 50 µg G6PD on Muller Hinton agar. Results were
interpreted using CLSI 2015 disc diffusion cut-offs for
E. coli in urinary tract isolates, that is, ≥16 as sensitive,
13–15 intermediate and ≤12 as resistant.11

Ethical approval
As this study was conducted on archived bacterial isolates
and not on patients’ samples, it was given exemption by the
ethical review committee Aga Khan University Hospital
(ERC# 3992-PAT-ERC-16).

Statistical analysis
Data entered in Microsoft Excel 2010® and imported to Stata
SE (version 12) was used to calculate MIC50 and MIC90.
MIC50 and MIC90 were defined as the lowest concentration
of the antibiotic at which 50% and 90% of the tested strains
were inhibited. Categorical and essential agreement between
VITEK and broth microdilution was calculated using Kappa
scores.

Results
The study included 251 strains. These included E. coli
39.04% (98/251) followed by K. pneumoniae 31% (78/251),
Raoultella spp. 15.5% (Raoultella terrigena and Raoultella
ornithinolytica) (39/251), Enterobacter spp. 7.5% (19/251),
Klebsiella oxytoca 5.1% (13/251) and Citrobacter spp.
1.1% (3/251). Details regarding source and characteristics
of patients from whom these isolates were obtained are
provided in Table S1.

MIC50 and MIC90

Colistin MICs by broth microdilution was performed on all
strains. MIC50 value was calculated to be 0.5 µg/mL, whereas
MIC90 was 16 µg/mL. MIC50 and MIC90 values among different bacterial species was separately calculated (Figure 1).
Colistin MICs was ≥4 µg/mL in 40 out of 251 (15.9%)
study strains which were identified as being colistin resistant.
Infection and Drug Resistance 2017:10
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Figure 1 Groups of Enterobacteriaceae with MIC ranges from 0.03 to 16 μg/mL.

Out of these 40 strains 50% were K. pneumonia (n: 20),
22.5% R. terrigena (n:10), 10% Enterobacter spp. (n:4),
7.5% E. coli (n:3) and 7.5% K. oxytoca (n:3).

Agreement between VITEK and broth
VITEK MICs were available for 149 strains and agreement
was calculated. Broth and VITEK showed 100% categorical
agreement with kappa score of 1, CI (0.84–1.16). Essential
agreement was calculated to be 88.59% with kappa score of
0.7334, CI (0.6–0.798).

Fosfomycin susceptibility
Among this CRE collection, rate of fosfomycin resistance
was 12.3% (31/251). In the colistin-resistant CRE subgroup
(n:40) 35 out of 40 remained susceptible to fosfomycin while
5 stains were found resistant to both colistin and fosfomycin
simultaneously.

Discussion
Multidrug resistant (MDR) and extensively drug resistant
(XDR) bacteria are a global threat. In countries with limited
resources, over-stretched health systems make it difficult to
manage such infections. Furthermore, inadequate implementation of infection control policies contribute toward
dissemination of both nosocomial infections as well as of
antimicrobial resistance.

Infection and Drug Resistance 2017:10

Our study showed 15.9% colistin and 12.3% fosfomycin
resistance among CREs. Both colistin and fosfomycin are
salvage antibiotics for treating MDR and XDR infections.
Hence emerging resistance against these agents significantly
reduces available treatment options. Despite their potential
side effects and high cost, in the absence of alternatives,
clinicians have had no option but to use these antibiotics.
Aga Khan University hospital is a 680-bedded tertiary care
hospital which caters to thousands of patients all year round.
Our laboratory has more than 200 collection units and participates in external quality assurance surveys from College
of American Pathologist on regular basis. Since rate of CRE
in the hospital has been increasing over time, colistin or fosfomycin are only prescribed for patients on clinician’s advice
and their use is closely monitored by the pharmacy service.
As per Antibiotic policy of the hospital, IV fosfomycin and
colistin have been labeled as restricted and controlled antibiotics which require mandatory approval from the infectious
diseases pharmacist or ID physician for dispense.
Colistin resistance among CRE has been previously
reported. Most of these studies have been case reports or outbreaks in hospital settings. An outbreak in three institutions
in Detroit, MI, USA reported a cluster of colistin-resistant,
carbapenem-resistant K. pneumoniae infection in 2009.14
Another study from Italy also reported emergence of colistin
resistance in carbapenem-resistant K. pneumoniae strains
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c ollected from 21 hospital laboratories during November
2013 to April 2014.15 Goel et al reported emergence of a
cluster of 24 cases of colistin resistant K. pneumoniae in
oncology unit in India.16
Earlier, colistin resistance was known to be mediated by
chromosomal mutations which altered the lipopolysaccharide of the bacterial outer membrane. These include mgrB,
phoP/phoQ, pmrA, pmrB, pmrC, and crrABC.17 In 2015, a
study from China reported emergence of plasmid mediated
colistin resistance (mcr-1) in E. coli and K. pneumoniae
from human and animals.18 A variant of mcr-1 (mcr-1.2) and
mcr-2 were also detected in Italy and Belgium.19,20 Rapid rise
of resistance in such a brief period is alarming and poses a
major threat in countries with high CRE prevalence such as
Pakistan, further minimizing available antibiotic options for
treatment of CRE infections.
Due to excessive and inappropriate use of colistin, resistance has not only emerged among CRE but other bacterial
species as well. In 2002, an outbreak of colistin-resistant
Pseudomonas aeruginosa in a pulmonology unit in the UK
created an infection control concern,21 over the years this was
followed with different reports from Australia, India and Iran
where colistin resistance was documented in Acinetobacter
baumanii as well.22–24
With limited available options for treating CRE infections, fosfomycin held promise. An earlier study on 152 MDR
(including 85 XDR) Enterobacteriaceae isolates, reported
overall susceptibility against fosfomycin of 92.8% (141/152).25
These findings concurred with another study published in
the same year, 2009, reporting 7% fosfomycin resistance in
prospectively collected 68 K. pneumoniae isolates of which
23 were also nonsusceptible to tigecycline and/or colistin.26 A
recent study from Germany in 2013 tested fosfomycin against
CRE and reported 78% of the tested strain as fosfomycin sensitive.27 Hence, our data reporting 12.3% resistance in CRE
suggests increasing resistance against this antibiotic.
Our study has few limitations. Due to financial constrain
test strains were only identified on basis of biochemical identification using API 20E. Neither molecular identification of
the isolates, nor resistance gene detection was performed for
mcr-1, mrgB or other mutations. Hence additional studies are
required to identify genetic mutations associated with colistin
resistance in this part of the world. As we tested colistin and
fosfomycin using two different methods (broth microdilution
and disc diffusion) we could not look for synergism and, therefore, further studies are needed to evaluate synergy between
different antibiotics combination for the treatment of CRE.

234

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

Conclusion
Our data suggest emerging in vitro resistance against colistin
and fosfomycin in CREs from Pakistan. Our findings suggest
a need for regular monitoring of antimicrobial resistance in
the country including for colistin and fosfomycin. Our data
further highlights the urgency for developing and implementing a national policy toward control of antimicrobial
resistance in Pakistan.
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Table S1 General characteristics of the bacterial isolates
included in the study
General characteristics of the study

N=251

Mean, age
Gender
Male (%)
Female (%)
Site of organism recovery
Urine
Blood
Cerebrospinal fluid
Pus
Tissue
Respiratory specimen
Other body fluids

50.9 years
56.8
43.13
143
61
4
11
7
14
11
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